Holiday Apartments:Pyla Village Resort Larnaca:Cyprus

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C Anadys Pharmaceuticals.

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C Anadys Pharmaceuticals, Inc. Announced today that dosing has begun in the Stage IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C individuals http://www.silagra-rx.com/what-is-sildenafil.html . THE BUSINESS expects to get Week 8 antiviral response data for treatment-naive individuals by the finish of the second one fourth of 2011, Week 12 antiviral response data for treatment-experienced individuals in the third quarter of 2011 and Week 24 antiviral response data for both groups in the fourth one fourth of 2011.